Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 × 10⁹/L

References

• Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125:3246–3252. doi:10.1182/blood-2014-10-55150725778528
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi:10.1182/blood-2016-03-64354427069254
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.27895058
   PubMed Web of Science ®Google Scholar
• Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11. doi:10.1111/bjh.2004.127.issue-115384972
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330. doi:10.1055/s-0037-161606811816725
   PubMed Web of Science ®Google Scholar
• Toh CH, Hoots WK; SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost. 2007;5:604–606. doi:10.1111/jth.2007.5.issue-317096704
   PubMed Web of Science ®Google Scholar
• Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017;10:147–154. doi:10.1080/17474086.2017.127075427967252
   PubMed Web of Science ®Google Scholar
• Zheng CC, Zhu XY, Tang BL, et al. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML. Bone Marrow Transplant. 2017;52:88–94. doi:10.1038/bmt.2016.18227376453
   PubMed Web of Science ®Google Scholar
• Iacobelli S; EBMT Statistical Committee. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48:S1–37. doi:10.1038/bmt.2012.282
   PubMed Web of Science ®Google Scholar
• Dignan FL, Clark A, Amrolia P, et al.; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30–45. doi:10.1111/bjh.2012.158.issue-122533831
   PubMed Web of Science ®Google Scholar
• Dignan FL, Amrolia P, Clark A, et al.; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol. 2012;158:46–61. doi:10.1111/bjh.2012.158.issue-122533811
   PubMed Web of Science ®Google Scholar
• Tien FM, Hou HA, Tsai CH, et al. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. Eur J Haematol. 2018;101:86–94. doi:10.1111/ejh.1307329624746
   PubMed Web of Science ®Google Scholar
• Tsai CH, Hou HA, Tang JL, et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia. 2016;30:1485–1492. doi:10.1038/leu.2016.6527055875
   PubMed Web of Science ®Google Scholar
• How J, Sykes J, Gupta V, et al. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer. 2012;118:6110–6117. doi:10.1002/cncr.2768322736495
   PubMed Web of Science ®Google Scholar
• de Jonge HJ, Valk PJ, de Bont ES, et al. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica. 2011;96:1310–1317. doi:10.3324/haematol.2011.04059221606167
   PubMed Web of Science ®Google Scholar
• Fröhling S, Schlenk RF, Breitruck J, et al.; AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–4380. doi:10.1182/blood-2002-05-144012393388
   PubMed Web of Science ®Google Scholar
• Heiblig M, Labussière-Wallet H, Nicolini FE, et al. Prognostic value of genetic alterations in elderly patients with acute myeloid leukemia: a single institution experience. Cancers (Basel). 2019;11:570. doi:10.3390/cancers11040570
   PubMed Web of Science ®Google Scholar
• Mueller BU, Seipel K, Pabst T. Myelodysplastic syndromes and acute myeloid leukemias in the elderly. Eur J Intern Med. 2018;58:28–32. doi:10.1016/j.ejim.2018.05.02630527920
   PubMed Web of Science ®Google Scholar
• Rao AV. Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction. Hematology Am Soc Hematol Educ Program. 2016;2016:339–347. doi:10.1182/asheducation-2016.1.33927913500
   PubMed Web of Science ®Google Scholar
• Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018;59:274–287. doi:10.1080/10428194.2017.133095628573892
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu X, Liu H, et al. A comparative study of idarubicin 12 mg/m(2) and 8 mg/m(2) combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients. Onco Targets Ther. 2016;9:985–991. doi:10.2147/OTT.S9617627013891
   PubMed Web of Science ®Google Scholar
• Canaani J, Labopin M, Socié G, et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT. Am J Hematol. 2017;92:653–659. doi:10.1002/ajh.2473728370339
   PubMed Web of Science ®Google Scholar